ASCO Guidelines

175 Episodes

1. Considerations for the Use of Steroids: Management of irAEs Guideline (Part 13)

   Published: 11/16/2021
2. Ocular Toxicities: Management of irAEs Guideline (Part 12)

   Published: 11/15/2021
3. Cardiovascular Toxicities: Management of irAEs Guideline (Part 11)

   Published: 11/12/2021
4. Hematologic Toxicities: Management of irAEs Guideline (Part 10)

   Published: 11/11/2021
5. Nervous System Toxicities: Management of irAEs Guideline (Part 9)

   Published: 11/10/2021
6. Renal Toxicities: Management of irAEs Guideline (Part 8)

   Published: 11/9/2021
7. Musculoskeletal Toxicities: Management of irAEs Guideline (Part 7)

   Published: 11/8/2021
8. Endocrine Toxicities: Management of irAEs Guideline (Part 6)

   Published: 11/5/2021
9. Lung Toxicities: Management of irAEs Guideline (Part 5)

   Published: 11/4/2021
10. Gastrointestinal Toxicities: Management of irAEs Guideline (Part 4)

    Published: 11/3/2021
11. Cutaneous Toxicities: Management of irAEs Guideline (Part 3)

    Published: 11/2/2021
12. CAR-T Cell Therapy: Management of irAEs Guideline (Part 2)

    Published: 11/1/2021
13. ICPi Overview: Management of irAEs Guideline (Part 1)

    Published: 11/1/2021
14. Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendation Update

    Published: 8/18/2021
15. Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

    Published: 8/3/2021
16. Chemotherapy and Targeted Therapy for Patients with Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative Guidelin

    Published: 7/29/2021
17. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Guideline Update

    Published: 7/29/2021
18. Telehealth in Oncology: Standards and Practice Recommendations

    Published: 7/28/2021
19. Salivary Gland Hypofunction and/or Xerostomia Induced by Non-Surgical Cancer Therapies: ISOO/MASCC/ASCO Guideline

    Published: 7/20/2021
20. Management of the Axilla in Early-Stage Breast Cancer: OH (CCO) and ASCO Guideline

    Published: 7/19/2021